Regenxbio Inc (RGNX)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $505.18M
Last updated: Nov 17, 2026 at 11:05 AM ET
Regenxbio Inc (RGNX) Competitors
The companies most similar to Regenxbio are Neurogene (NGNE), PepGen (PEPG) and Tevogen Bio Holdings (TVGN). By market cap, Regenxbio ranks 3rd of the 13 companies on this page; Nuvectis Pharma (NVCT) is the largest at $696.03M.
Peer Comparison
RGNX's revenue growth of -69.2% is below the peer median of 0.0%. Like the median peer, it pays no dividend.
| Company | Market cap | P/E | P/S | Net margin | ROIC | Rev growth | Div yield |
|---|---|---|---|---|---|---|---|
| Regenxbio (RGNX) | $505.18M | N/A | 3.1x | -113.9% | N/A | -69.2% | 0.00% |
| Neurogene Inc (NGNE) | $495.37M | N/A | N/A | 0.0% | -28.5% | 0.0% | 0.00% |
| PepGen Ltd (PEPG) | $410.98M | N/A | N/A | 0.0% | N/A | 0.0% | 0.00% |
| Tevogen Bio Holdings Inc. (TVGN) | $406.59M | N/A | N/A | 0.0% | 2022.8% | 0.0% | 0.00% |
| Rezolute Inc (RZLT) | $353.54M | N/A | N/A | 0.0% | N/A | 0.0% | 0.00% |
| Entera Bio Ltd (ENTX) | $541.57M | N/A | N/A | 0.0% | -8.5% | -100.0% | 0.00% |
| Rocket Pharmaceuticals Inc (RCKT) | $256.82M | N/A | N/A | 0.0% | -2.3% | 0.0% | 0.00% |
| Precision BioSciences Inc (DTIL) | $288.76M | N/A | 4.4x | -85.6% | -38.3% | 37272.0% | 0.00% |
| Gyre Therapeutics Inc. (GYRE) | $471.74M | N/A | 3.8x | -22.7% | N/A | 0.7% | 0.00% |
| Prothena Corporation plc (PRTA) | $419.01M | N/A | 7.8x | -45.4% | N/A | -74.3% | 0.00% |
| Opus Genetics, Inc. (IRD) | $384.68M | N/A | 52.0x | 0.0% | -145.1% | -63.1% | 0.00% |
| Kyverna Therapeutics, Inc. Common Stock (KYTX) | $319.27M | N/A | N/A | 0.0% | -81.5% | 0.0% | 0.00% |
| Nuvectis Pharma Inc (NVCT) | $696.03M | N/A | N/A | 0.0% | N/A | 0.0% | 0.00% |
| Peer median | $408.79M | N/A | 6.1x | 0.0% | -28.5% | 0.0% | 0.00% |
Similar Companies
These are the 12 companies most similar to Regenxbio, ranked by how closely their business, size, sector and industry match. All 12 are in one industry, Biotechnology.
| Company | About | Peers |
|---|---|---|
| Neurogene Inc (NGNE) | Neurogene Inc. is an innovative biotechnology company at the forefront of developing advanced gene therapies for rare neurological disorders... | NGNE competitors |
| PepGen Ltd (PEPG) | PepGen Inc., a clinical-stage biotechnology company, is focused on the development of oligonucleotide therapeutics for use in the treatment of serious... | PEPG competitors |
| Tevogen Bio Holdings Inc. (TVGN) | Tevogen Bio Holdings Inc. is a clinical-stage biotechnology company that develops off-the-shelf precision T cell therapeutics in virology, oncology... | TVGN competitors |
| Rezolute Inc (RZLT) | Rezolute, Inc., a clinical-stage biopharmaceutical company, develops rare and metabolic disease therapies in the United States. | RZLT competitors |
| Entera Bio Ltd (ENTX) | Entera Bio Ltd., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of orally administered large molecule therapies... | ENTX competitors |
| Rocket Pharmaceuticals Inc (RCKT) | Rocket Pharmaceuticals, Inc., is a cross-platform biotechnology company focused on developing gene therapies for rare and devastating pediatric diseases. | RCKT competitors |
| Precision BioSciences Inc (DTIL) | Precision BioSciences, Inc., a genome editing company, develops therapeutic products in the United States. | DTIL competitors |
| Gyre Therapeutics Inc. (GYRE) | Gyre Therapeutics Inc. is a pioneering biopharmaceutical company at the forefront of developing advanced therapies for rare and complex diseases. | GYRE competitors |
| Prothena Corporation plc (PRTA) | Prothena Corporation plc, an advanced stage clinical company, is focused on the discovery and development of new therapies for life-threatening diseases... | PRTA competitors |
| Opus Genetics, Inc. (IRD) | Opus Genetics, Inc. (IRD) is a pioneering biotechnology company dedicated to advancing gene therapies for rare retinal diseases that affect vision. | IRD competitors |
| Kyverna Therapeutics, Inc. Common Stock (KYTX) | Kyverna Therapeutics, Inc. is an innovative biotechnology company focused on advancing immunotherapies for autoimmune diseases and other significant health... | KYTX competitors |
| Nuvectis Pharma Inc (NVCT) | Nuvectis Pharma, Inc., a biopharmaceutical company, is focused on the development of targeted small molecule therapies for the treatment of cancer. | NVCT competitors |
Frequently Asked Questions About RGNX
Who are Regenxbio's main competitors?
The companies most similar to Regenxbio include Neurogene (NGNE), PepGen (PEPG), Tevogen Bio Holdings (TVGN), Rezolute (RZLT) and Entera Bio (ENTX), listed from the closest match.
Who is Regenxbio's biggest competitor?
Nuvectis Pharma (NVCT) is the largest of the similar companies at $696.03M; Neurogene (NGNE) is the closest match by business profile, size, sector and industry.
How does RGNX stock compare with its competitors?
RGNX's P/S is 3.1x against a peer median of 6.1x; its net margin is -113.9% against a peer median of 0.0%.
Which of Regenxbio's competitors pays a higher dividend?
Regenxbio pays no dividend. None of the similar companies with available yields has a higher forward dividend yield.
Is Regenxbio bigger than its competitors?
No. Regenxbio is 3rd by market cap among the 13 companies on this page; the largest is Nuvectis Pharma (NVCT) at $696.03M.
RGNX pages: Overview, Earnings, Forecast, Financials, Competitors